Rheumatology

For more than two decades, Johnson & Johnson has been providing patients and physicians with important therapies to treat rheumatoid arthritis (RA) and other rheumatic diseases, beginning with the development of tumor necrosis factor (TNF)-alpha inhibitors and continuing with the establishment of the first interleukin (IL)-12/IL-23 treatment.

We remain focused on complementing our existing portfolio of large-molecule biologics with novel treatments and oral therapeutics in development to provide new options to patients, through a combination of internal research and development, external collaborations, and industry consortia. We are also advancing research in autoantbody-driven rheumatic diseases, such as idiopathic inflammatory myopathies (IIM), Sjögren’s disease (SjD), and Systemic Lupus Erythematosus (SLE).

Keeping patients at the center of everything we do, Johnson & Johnson is committed to tirelessly pushing the boundaries of science to deliver innovative and transformational approaches for heumatic diseases building on the ever-evolving understanding of the immune system.